Amazon’s Weight-Loss Drug Move Isn’t About Obesity. It’s About Owning Healthcare.
Amazon’s move to distribute GLP-1 weight-loss drugs through Medicare Part D looks like a play on the obesity trend. It’s not. It’s the first step in building a scalable pharmacy fulfillment infrastructure for chronic disease management — one that could make Amazon the default middleman for how America gets its prescriptions, reshaping drug pricing, patient access, and the entire pharmacy industry in the process.